Skibo E B
Biochemistry. 1986 Jul 29;25(15):4189-94. doi: 10.1021/bi00363a004.
Benzimidazole derivatives possessing a leaving group in the 2 alpha-position and either 4,7-dione, 4,7-diol, or 4,7-dimethoxy substituents were examined as inhibitors of buttermilk xanthine oxidase. The quinone and hydroquinone derivatives are not inhibitors of xanthine-oxygen reductase activity, even though the latter is a powerful alkylating agent. The methoxylated hydroquinones are linear noncompetitive inhibitors, the best of which is the 2 alpha-bromo analogue (Ki = 46 microM). During xanthine-oxygen reductase activity, the 2 alpha-bromo analogue irreversibly traps the reduced enzyme. Formation of a C(4a) adduct of the reduced functional FAD cofactor is postulated on the basis of UV-visible spectral evidence and reconstitution of the enzyme after removal of the altered FAD. A probable sequence of events is reversible binding at or near the reduced cofactor followed by adduct formation. It is concluded that potent tight binding inhibitors could be designed that act at the FAD cofactor rather than the purine active site.
对在2α-位带有离去基团且具有4,7-二酮、4,7-二醇或4,7-二甲氧基取代基的苯并咪唑衍生物作为酪乳黄嘌呤氧化酶抑制剂进行了研究。醌和对苯二酚衍生物不是黄嘌呤-氧还原酶活性的抑制剂,尽管后者是一种强烷基化剂。甲氧基化对苯二酚是线性非竞争性抑制剂,其中最好的是2α-溴类似物(Ki = 46 μM)。在黄嘌呤-氧还原酶活性过程中,2α-溴类似物不可逆地捕获还原态酶。基于紫外-可见光谱证据以及去除改变的黄素腺嘌呤二核苷酸(FAD)后酶的重组,推测还原态功能性FAD辅因子形成了C(4a)加合物。可能的事件顺序是在还原态辅因子处或其附近可逆结合,随后形成加合物。得出的结论是,可以设计出在FAD辅因子而非嘌呤活性位点起作用的强效紧密结合抑制剂。